Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Silence Therapeutics (SLN) Shares Outstanding (Diluted Average): 2022-2024

Historic Shares Outstanding (Diluted Average) for Silence Therapeutics (SLN) over the last 3 years, with Dec 2024 value amounting to $138.8 million.

  • Silence Therapeutics' Shares Outstanding (Diluted Average) fell 22.76% to $141.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $141.7 million, marking a year-over-year decrease of 22.76%. This contributed to the annual value of $138.8 million for FY2024, which is 0.46% up from last year.
  • Per Silence Therapeutics' latest filing, its Shares Outstanding (Diluted Average) stood at $138.8 million for FY2024, which was up 0.46% from $138.1 million recorded in FY2023.
  • Silence Therapeutics' 5-year Shares Outstanding (Diluted Average) high stood at $138.8 million for FY2024, and its period low was $119.5 million during FY2022.
  • Over the past 3 years, Silence Therapeutics' median Shares Outstanding (Diluted Average) value was $138.1 million (recorded in 2023), while the average stood at $132.1 million.
  • Per our database at Business Quant, Silence Therapeutics' Shares Outstanding (Diluted Average) rose by 15.54% in 2023 and then dropped by 0.46% in 2024.
  • MRY analysis of 3 years shows Silence Therapeutics' Shares Outstanding (Diluted Average) stood at $119.5 million in 2022, then grew by 15.54% to $138.1 million in 2023, then increased by 0.46% to $138.8 million in 2024.
  • Its Shares Outstanding (Diluted Average) was $138.8 million in FY2024, compared to $138.1 million in FY2023 and $119.5 million in FY2022.